COVID-19 Test Profits Make Labs Potential Target for Public Backlash
Independent labs accrued a profit of at least $10 on each PCR COVID-19 test performed in the period from May to December 2020, study says.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LAB INDUSTRY REPORT
NATIONAL LAB REPORTER
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Independent labs accrued a profit of at least $10 on each PCR COVID-19 test performed in the period from May to December 2020, study says.
Now that the finishing touches have been put on LDT-related legislation, what is the likelihood that it will pass?
Two of the biggest merger and acquisition-related deals that came down in May involved BioMérieux and Sema4
Senate committee members propose a modified version of legislation allowing the FDA to continue to regulate LDTs on a risk-tiered basis.
Companies will explore LabDroid’s capacity to automate sample preparation workflows for long-read sequencing systems.
Companies are using the lessons learned from COVID-19 to get out of the box quickly in developing test kits for monkeypox.
Most diagnostics companies experienced modest, flat, or negative top-line revenue growth rates in the first quarter of 2022.
In this month’s Business Roundup, we cover key happenings include Medicare coverage and reimbursement, as well as the US surpassing Europe as medtech’s market of choice.
Healthcare M&A might have bottomed out in the first quarter of 2022 in terms of both deal volume and size, according to a new report.
InspectIR COVID-19 device detects the virus from breath samples in less than three minutes, offering a new screening option.
The recently-formed Precision Cancer Consortium will make it easier for cancer patients around the world to get access to genomic testing.